Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Remestemcel-L · Ryoncil, JR-0301

Cell therapy (Stem-cell derived) · Immune activation · developed by Mesoblast

Approved FDA, Dec 2024
MESO Developer
7 Registered trials

What is Remestemcel-L?

Remestemcel-L is an allogeneic cell therapy made of adult human mesenchymal stromal cells harvested from bone marrow of donors and expanded ex vivo. Its immunomodulatory activity is thought to involve inhibition of T cell activation and pro-inflammatory cytokine secretion. It is studied in graft versus host disease, Crohn's disease, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ryoncil, JR-0301, Prochymal
Drug type
Cell therapy (Stem-cell derived)
Mechanism
Immune activation
Pathways
T cell activation inhibition, anti-inflammatory cytokine production
Therapy area
Gastroenterology, Immunology, Respiratory
Developer
Mesoblast (MESO)
FDA status
Approved as Ryoncil (December 18, 2024), BLA125706 · FDA label
UNII
H57D26Z9YK

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 11, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04371393 Phase 3 Mesenchymal Stromal Cells Terminated MESO
NCT00482092 Phase 3 Crohn's Disease Completed MESO
NCT00683722 Phase 2 Pulmonary Disease, Chronic Obstructive Completed MESO
NCT00294112 Phase 2 Crohn's Disease Completed MESO
NCT00284986 Phase 2 Graft Versus Host Disease Completed MESO
NCT00136903 Phase 2 Graft Vs Host Disease Completed MESO
NCT01510431 N/A Crohn's Disease No longer available MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Respiratory Distress SyndromeChronic BronchitisCOVIDCrohn's DiseaseGraft Versus Host DiseaseGraft Vs Host DiseaseMesenchymal Stromal CellsPulmonary Disease, Chronic ObstructivePulmonary EmphysemaRemestemcel-L

More from Mesoblast

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind Remestemcel-L

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.